UroGen News and Activities
Presence
UroGen develops and sells treatments for urologic cancers and related diseases. Its products and clinical programs serve hospitals, urology specialists, and cancer patients in the United States.
UroGen products and services overview:
- Cancer therapies
- Urology treatments
- Drug delivery
- Oncology research
Revenue: ~$92 million
Employees: 300
Headquarters: Princeton, United States (USA)
UroGen is one of the...
UroGen is a company listed under the stock ticker URGN (US).
Executives
View the org chart displaying its 31 main executives
Most searched biographies at UroGen
- Elizabeth Barrett, Director, President and Chief Executive Officer
- Cynthia Butitta, Director
- Dan Wildman, Director
Popular executive movements at UroGen
- Jennifer Ham, who was Regional Operations Manager, is promoted to Senior Regional Operations Manager, West (posted on February 26 2026).
- Robert Folts has joined the company as Vice President of Sales (posted on February 26 2026).
Create your alert
to follow the executive moves at UroGen.
Biotechnology
UroGen has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
- NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
- Rallybio and Avenzo Therapeutics have announced they will merge (posted on June 1 2026)..
Popular contacts in Biotechnology
News
Press releases by UroGen
- UroGen Pharma to Present at Upcoming Investor Conferences | Urogen Pharma Inc.
- News Releases | Urogen Pharma Inc.
- News Releases | Urogen Pharma Inc.
- The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | Urogen Pharma Inc.
- UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments | Urogen Pharma Inc.
- News Releases | Urogen Pharma Inc.
- UroGen Announces $120 Million Private Placement of Ordinary Shares | Urogen Pharma Inc.
- UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Urogen Pharma Inc.
- UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials | Urogen Pharma Inc.
- UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 | Urogen Pharma Inc.
- View more press releases Close
Social media about UroGen
- UroGen on Wikipedia, Google News & Yahoo Finance
- UroGen on LinkedIn, X (Twitter) & YouTube
